Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Endocrine therapy for advanced breast cancer].

Yoshinami T, Yagi T, Ishitobi M.

Nihon Rinsho. 2012 Sep;70 Suppl 7:641-4. Japanese. No abstract available.

PMID:
23350477
2.

Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.

Aapro M.

Anticancer Drugs. 2008 Mar;19 Suppl 2:S1. doi: 10.1097/01.cad.0000277610.08129.06. No abstract available.

PMID:
18337639
3.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer.

J Clin Oncol. 2001 Jan 15;19(2):343-53.

PMID:
11208825
4.

[Hormone therapy for breast cancer].

Saito Y, Suzuki Y, Tokuda Y.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:543-8. Review. Japanese. No abstract available.

PMID:
17682208
5.

Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.

Tan SH, Wolff AC.

Clin Breast Cancer. 2007 Feb;7(6):455-64. Review.

PMID:
17386122
6.

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, OcaƱa A.

J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. Review.

7.

The influence of endocrine treatments for breast cancer on health-related quality of life.

Buijs C, de Vries EG, Mourits MJ, Willemse PH.

Cancer Treat Rev. 2008 Nov;34(7):640-55. doi: 10.1016/j.ctrv.2008.04.001. Epub 2008 Jun 2. Review.

PMID:
18514425
8.

Letrozole in the neoadjuvant setting: the P024 trial.

Ellis MJ, Ma C.

Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):371.

9.

Overcoming resistance: targeting the PI3K/mTOR pathway in endocrine refractory breast cancer.

Butt AJ.

Cancer Biol Ther. 2011 Jun 1;11(11):947-9. Epub 2011 Jun 1. No abstract available.

PMID:
21577052
10.

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.

Cancer Treat Rev. 2008 Apr;34(2):157-74. doi: 10.1016/j.ctrv.2007.11.001. Epub 2007 Dec 31. Review.

PMID:
18164821
11.

Tamoxifen therapy for patients with breast cancer.

Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G.

Lancet. 2013 Jun 15;381(9883):2077-8. doi: 10.1016/S0140-6736(13)61236-2. No abstract available.

PMID:
23769223
12.

Recent perspectives of endocrine therapy for breast cancer.

Utsumi T, Kobayashi N, Hanada H.

Breast Cancer. 2007;14(2):194-9. Review.

13.

Fertility preservation in (breast) cancer patients: is it safe?

Wildiers H, Neven P, Amant F, D'hooghe T, Paridaens R.

J Clin Oncol. 2006 Nov 20;24(33):5335-6; author reply 5337-8. No abstract available.

14.

[The evolving role of endocrine therapy for breast cancer].

Jinno H, Ikeda T, Takayama S, Kitajima M.

Nihon Rinsho. 2006 Mar;64(3):547-54. Review. Japanese.

PMID:
16529048
15.

Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.

Cunnick G, Mokbel K.

Int J Fertil Womens Med. 2005 Sep-Oct;50(5 Pt 1):197-8.

PMID:
16468468
16.

Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.

Singh Ranger G.

J Clin Pharm Ther. 2005 Aug;30(4):313-7. Review. Erratum in: J Clin Pharm Ther. 2005 Oct;30(5):496. Sing Ranger, G [corrected to Singh Ranger, G].

PMID:
15985044
17.

A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.

Zucchini G, Armstrong AC, Wardley AM, Wilson G, Misra V, Seif M, Ryder WD, Cope J, Blowers E, Howell A, Palmieri C, Howell SJ.

Eur J Cancer. 2015 Dec;51(18):2725-31. doi: 10.1016/j.ejca.2015.08.028. Epub 2015 Nov 18.

PMID:
26597446
18.

[A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].

Baba S, Oji Y, Teramoto M, Kawabata K, Saito A.

Gan To Kagaku Ryoho. 2009 Nov;36(11):1905-6. Japanese.

PMID:
19920398
19.

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

Spicer J, Ellis P.

Cancer Lett. 2007 Apr 18;248(2):165-74. Epub 2006 Aug 21. Review.

PMID:
16919870
20.

Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.

Tobias JS.

Int J Biochem Cell Biol. 2004 Nov;36(11):2112-9. Review.

PMID:
15313457
Items per page

Supplemental Content

Write to the Help Desk